Pityriasis Rosea
Antonio A.T. Chuh
Department of Family Medicine and Primary Care, The University of Hong Kong and Queen Mary Hospital, Pokfulam, Hong Kong
JC School of Public Health and Primary Care, The Chinese University of Hong Kong and the Prince of Wales Hospital, Shatin, Hong Kong
Search for more papers by this authorVijay Zawar
Skin Diseases Centre, Nashik, India
Department of Dermatology, MVP's Dr Vasantrao Pawar Medical College and Research Centre, Nashik, Maharashtra, India
Search for more papers by this authorAntonio A.T. Chuh
Department of Family Medicine and Primary Care, The University of Hong Kong and Queen Mary Hospital, Pokfulam, Hong Kong
JC School of Public Health and Primary Care, The Chinese University of Hong Kong and the Prince of Wales Hospital, Shatin, Hong Kong
Search for more papers by this authorVijay Zawar
Skin Diseases Centre, Nashik, India
Department of Dermatology, MVP's Dr Vasantrao Pawar Medical College and Research Centre, Nashik, Maharashtra, India
Search for more papers by this authorPeter Hoeger
Search for more papers by this authorVeronica Kinsler
Search for more papers by this authorAlbert Yan
Search for more papers by this authorJohn Harper
Search for more papers by this authorArnold Oranje
Search for more papers by this authorChristine Bodemer
Search for more papers by this authorMargarita Larralde
Search for more papers by this authorVibhu Mendiratta
Search for more papers by this authorDiana Purvis
Search for more papers by this authorSummary
Pityriasis rosea is a self-limited exanthem likely to be related to viral infections, particularly endogenous reactivation or primary infection of human herpesviruses 7 and 6.
A prodrome of coryzal symptoms is common. In around 20–30% of childhood cases, a herald patch is seen. The secondary generalized eruption then occurs 2–3 weeks later, with usually smaller macules with peripheral collarette scaling on the trunk and proximal aspects of the extremities. The orientation of most lesions follows lines of skin creases. Spontaneous remission then occurs 2–12 weeks after the eruption of the herald patch or the generalized eruption.
Many children exhibit atypical variants of this exanthem. Validated diagnostic criteria are available and are particularly applicable for children with marginal symptoms. Classification systems are available for delineating subclasses, and allow for choice of treatment modalities as well as subgroup analyses in laboratory-based and clinical investigations.
Pityriasis rosea usually does not have significant impacts on children and adolescents. Symptomatic treatments usually suffice. The benefits of active interventions with antiviral agents are being actively investigated.
References
- Feinstein A, Kahana M. Pityriasis rosea of Gibert. J Am Acad Dermatol 1987; 16: 1260.
-
Percival GH. Pityriasis rosea. Br J Dermatol 1932; 44: 241–53.
10.1111/j.1365-2133.1932.tb09599.x Google Scholar
- Klauder JV. Pityriasis rosea with particular reference to its unusual manifestations. JAMA 1924; 82: 178–83.
- Sarkany I, Hare PJ. Pityriasis rotunda (pityriasis circinata). Br J Dermatol 1964; 76: 223–7.
-
Weiss L. Pityriasis rosea – an erythematous eruption of internal origin. JAMA 1903; 41: 20–8.
10.1001/jama.1903.04470030024006 Google Scholar
- De Souza Sittart JA, Tayah M, Soares Z. Incidence pityriasis rosea of Gibert in the Dermatology Service of the Hospital do Servidor Publico in the state of Sao Paulo. Med Cutan Ibero Lat Am 1984; 12: 336–8.
- Olumide Y. Pityriasis rosea in Lagos. Int J Dermatol 1987; 26: 234–6.
- Vollum DI. Pityriasis rosea in the African. Trans St Johns Hosp Dermatol Soc 1973; 59: 269–71.
- Jacyk WK. Pityriasis rosea in Nigerians. Int J Dermatol 1980; 19: 397–9.
- Ahmed MA. Pityriasis rosea in the Sudan. Int J Dermatol 1986; 25: 184–5.
- Giam YC. Skin diseases in children in Singapore. Ann Acad Med Singapore 1988; 17: 569–72.
- Harman M, Aytekin S, Akdeniz S, Inaloz HS. An epidemiological study of pityriasis rosea in Eastern Anatolia. Eur J Epidemiol 1998; 14: 495–7.
- Nanda A, Al-Hasawi F, Alsaleh QA. A prospective survey of pediatric dermatology clinic patients in Kuwait: an analysis of 10,000 cases. Pediatr Dermatol 1999; 16: 6–11.
- Tay YK, Goh CL. One-year review of pityriasis rosea at the National Skin Centre, Singapore. Ann Acad Med Singapore 1999; 28: 829–31.
- Traore A, Korsaga-Some N, Niamba P et al. Pityriasis rosea in secondary schools in Ouagadougou, Burkina Faso. Ann Dermatol Venereol 2001; 128: 605–9.
- Messenger AG, Knox EG, Summerly R et al. Case clustering in pityriasis rosea: support for role of an infective agent. BMJ (Clin Res Ed) 1982; 284: 371–3.
- Chuang TY, Ilstrup DM, Perry HO, Kurland LT. Pityriasis rosea in Rochester, Minnesota, 1969 to 1978. J Am Acad Dermatol 1982; 7: 80–9.
- Abercrombie GF. Pityriasis rosea. Proc Roy Soc Med 1962; 55: 556–7.
- Cheong WK, Wong KS. An epidemiological study of pityriasis rosea in Middle Road Hospital. Singapore Med J 1989; 30: 60–2.
- Sharma L, Srivastava K. Clinicoepidemiological study of pityriasis rosea. Indian J Dermatol Venereol Leprol 2008; 74: 647–9.
- Ayanlowo O, Akinkugbe A, Olumide Y. The pityriasis rosea calendar: a 7 year review of seasonal variation, age and sex distribution. Nig Q J Hosp Med 2010; 20: 29–31.
- Ganguly S. A clinicoepidemiological study of pityriasis rosea in South India. Skinmed 2013; 11: 141–6.
- Özyürek GD, Alan S, Cenesizoğlu E. Evaluation of clinico-epidemiological and histopathological features of pityriasis rosea. Postepy Dermatol Alergol 2014; 31: 216–21.
- Björnberg A, Hellgren L. Pityriasis rosea. A statistical, clinical and laboratory investigation of 826 patients and matched healthy controls. Acta Derm Venereol 1962; 42(suppl 50): 1–50.
- Jawade SA, Chugh VS, Gohil SK et al. A clinico-etiological study of dermatoses in pediatric age group in tertiary health care center in South Gujarat Region. Indian J Dermatol 2015; 60: 635.
- Hendricks AA, Lohr JA. Pityriasis rosea in infancy. Arch Dermatol 1979; 115: 896–7.
- Hyatt H. Pityriasis rosea in a three month old. Arch Pediatr 1960; 77: 364.
- Truhan AP. Pityriasis rosea. Am Fam Physician 1984; 29: 193–6.
- Drago F, Ciccarese G, Rebora A, Parodi A. Relapsing pityriasis rosea. Dermatology 2014; 229: 316–8.
- Chuh A, Lee A, Molinari N. Case clustering in pityriasis rosea – a multi-center epidemiologic study in primary care settings in Hong Kong. Arch Dermatol 2003; 139: 489–93.
- Chuh A, Molinari N, Sciallis G et al. Temporal case clustering in pityriasis rosea – a regression analysis on 1379 patients in Minnesota, Kuwait and Diyarbakýr, Turkey. Arch Dermatol 2005; 141: 767–71.
- Chuh AAT. The association of pityriasis rosea with cytomegalovirus, Epstein–Barr virus and parvovirus B19 infections – a prospective case control study by polymerase chain reaction and serology. Eur J Dermatol 2003; 13: 25–8.
- Bonafé JL, Icart J, Perpère M et al. Histopathologic, ultrastructural, immunologic and virologic study of Gibert's pityriasis rosea. Ann Dermatol Venereol 1982; 109: 855–61.
- Hudson LD, Adelman S, Lewis CW. Pityriasis rosea. Viral complement fixation studies. J Am Acad Dermatol 1981; 4: 544–6.
- Marcus-Farber BS, Bergman R, Ben Porath E et al. Serum antibodies to parvovirus B19 in patients with pityriasis rosea. Dermatology 1997; 194: 371.
- Raskin J. Possible dermatropic virus associated with pityriasis rosea. Preliminary study. Acta Derm Venereol 1968; 48; 474–81.
- Metz J. An electron microscopic investigation of the pityriasis rosea. J Cutan Pathol 1977; 4: 228.
- Neubert U, Ring J. Immunological monitoring in pityriasis rosea. 17th International Congress of Dermatology, Berlin, 1987: 464.
- Aractingi S, Morinet F, Mokni M et al. Absence of picornavirus genome in pityriasis rosea. Arch Dermatol Res 1996; 289: 60–1.
- Gjenero-Margan I, Vidovic R, Drazenovic V. Pityriasis rosea Gibert: detection of Legionella micdadei antibodies in patients. Eur J Epidermiol 1995; 11: 459–62.
- Chuh AAT, Chan HHL. Prospective case–control study of chlamydia, legionella and mycoplasma infections in patients with pityriasis rosea. Eur J Dermatol 2002; 12: 170–3.
- Hudson LD, Adelman S, Lewis CW. Pityriasis rosea. Viral complement fixation studies. J Am Acad Dermatol 1981; 4: 544–6.
- Ishibashi A, Ueda I, Fujita K. Pityriasis rosea Gibert and Mycoplasma pneumoniae infection. J Dermatol 1985; 12: 97–100.
- Drago F, Ranieri E, Malaguti F et al. Human herpesvirus 7 in pityriasis rosea. Lancet 1997; 349: 1367–8.
- Drago F, Ranieri E, Malaguti F, Battifoglio ML. Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin. Dermatology 1997; 195: 374–8.
- Drago F, Ranieri E, Malaguti F, Battifoglio ML. Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin. Dermatology 1997; 195: 374–8.
- Drago F, Malaguti F, Ranieri E et al. Human herpes virus-like particles in pityriasis rosea lesions: an electron microscopy study. J Cutan Pathol 2002; 29: 359–61.
- Broccolo F, Drago F, Careddu AM et al. Additional evidence that pityriasis is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol 2005; 124: 1234–40.
- Drago F, Broccolo F, Ciccarese G et al. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology 2015; 230: 23–6.
- Drago F, Broccolo F, Javor S et al. Evidence of human herpesvirus-6 and -7 reactivation in miscarrying women with pityriasis rosea. J Am Acad Dermatol 2014; 71: 198–9.
- Watanabe T, Sugaya M, Nakamura K, Tamaki K. Human herpesvirus 7 and pityriasis rosea. J Invest Dermatol 1999; 113: 288–9.
- Watanabe T, Kawamura T, Jacob SE et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. J Invest Dermatol 2002; 119: 793–7.
- Vág T, Sonkoly E, Kárpáti S et al. Avidity of antibodies to human herpesvirus 7 suggests primary infection in young adults with pityriasis rosea. J Eur Acad Dermatol Venereol 2004; 18: 738–40.
- Vág T, Sonkoly E, Kemeny B et al. Studies on the novel association of human herpesvirus-7 with skin diseases. Orv Hetil 2003; 144: 1623–9.
- Canpolat Kirac B, Adisen E, Bozdayi G et al. The role of human herpesvirus 6, human herpesvirus 7, Epstein–Barr virus and cytomegalovirus in the aetiology of pityriasis rosea. J Eur Acad Dermatol Venereol 2008; 14: 6.
- Kempf W, Adams V, Kleinhans M et al. Pityriasis rosea is not associated with human herpesvirus 7. Arch Dermatol 1999; 135: 1070–2.
- Yoshida M. Detection of human herpesvirus 7 in patients with pityriasis rosea and healthy individuals. Dermatology 1999; 199: 197.
- Yasukawa M, Sada E, Machino H, Fugita S. Reactivation of human herpesvirus 6 in pityriasis rosea. Br J Dermatol 1999; 140: 169–70.
- Kosuge H, Tanaka-Taya K, Miyoshi H et al. Epidemiological study of human herpesvirus-6 and human herpesvirus-7 in pityriasis rosea. Br J Dermatol 2000; 143: 795–8.
- Offidani A, Pritelli E, Simonetti O et al. Pityriasis rosea associated with herpesvirus 7 DNA. (correspondence) J Eur Acad Dermatol Venereol 2000; 14: 313–14.
- Chuh AAT, Chiu SSS, Peiris JSM. Human herpesvirus 6 and 7 DNA in peripheral blood leukocytes and plasma in patients with pityriasis rosea by polymerase chain reaction – a prospective case control study. Acta Derm Venereol 2001; 81: 289–90.
- Wong WR, Tsai CY, Shih SR, Chan HL. Association of pityriasis rosea with human herpesvirus-6 and human herpesvirus-7 in Taipei. J Formos Med Assoc 2001; 100: 478–83.
- Karabulut AA, Kocak M, Yilmaz N, Eksioglu M. Detection of human herpesvirus 7 in pityriasis rosea by nested PCR. Int J Dermatol 2002; 41: 563–7.
- Yildirim M, Aridogan BC, Baysal V, Inaloz HS. The role of human herpes virus 6 and 7 in the pathogenesis of pityriasis rosea. Int J Clin Pract 2004; 58: 119–21.
- Chuh AA, Peiris JS. Lack of evidence of active human herpesvirus 7 (HHV-7) infection in three cases of pityriasis rosea in children. Pediatr Dermatol 2001; 18: 381–3.
- Drago F, Ciccarese G, Broccolo F et al. Pityriasis rosea in children: clinical features and laboratory investigations. Dermatology 2015; 231: 9–14.
- Burch PRJ, Rowell NR. Pityriasis rosea – an auto-aggressive disease? Br J Dermatol 1970; 82: 549–60.
- Hosokawa H, Horio S, Takiuchi Y et al. Naturally occurring T lymphocytotoxic antibody in viral and related skin diseases. Acta Derm Venereol 1984; 64: 275–80.
- Chuh AAT. A prospective case control study of autoimmune markers in patients with pityriasis rosea. Clin Exp Dermatol 2003; 28: 449–50.
- Chuang TY, Perry HO, Ilstrup DM, Kurland LT. Recent upper respiratory tract infection and pityriasis rosea: a case–control study of 249 matched pairs. Br J Dermatol 1983; 108: 587–91.
- Okamoto H, Imamura S, Aoshima T et al. Dyskeratotic degeneration of epidermal cells in pityriasis rosea: light and electron microscopic studies. Br J Dermatol 1982; 107: 189–94.
- Kempf W, Burg G. Pityriasis rosea – a virus-induced skin disease? An update. Arch Virol 2000; 145: 1509–20.
- Drago F, Ciccarese G, Broccolo F et al. The role of cytokines, chemokines, and growth factors in the pathogenesis of pityriasis rosea. Mediators Inflamm 2015; 2015: 438963.
- Chuh AAT. Quality of life in children with pityriasis rosea – a prospective case control study. Pediatr Dermatol 2003; 20: 474–8.
- Cavanaugh RM Jr. Pityriasis rosea in children. A review. Clin Pediatr (Phila) 1983; 22: 200–3.
- Chuh AAT. Rash orientation in pityriasis rosea – a qualitative study. Eur J Dermatol 2002; 12: 253–6.
- Chuh A, Zawar V, Lee A. Atypical presentations of pityriasis rosea – case presentations. J Eur Acad Dermatol Venereol 2005; 19: 120–6.
- Chuh AA. Diagnostic criteria for pityriasis rosea: a prospective case control study for assessment of validity. J Eur Acad Dermatol Venereol 2003; 17: 101–3.
- Chuh A, Lee A, Zawar V. The diagnostic criteria of Gianotti-Crosti syndrome: are they applicable to children in India? Pediatr Dermatol 2004; 21: 542–7.
- Chuh A, Zawar V, Sciallis GF, Lee A. The diagnostic criteria of pityriasis rosea and Gianotti-Crosti syndrome – a protocol to establish diagnostic criteria of skin diseases. J R Coll Physicians Edinb 2015; 45: 218–25.
- Zawar V, Chuh A. Follicular pityriasis rosea. A case report and a new classification of clinical variants of the disease. J Dermatol Case Rep 2012; 6: 36–9.
- Drago F, Ciccarese G, Rebora A et al. Pityriasis rosea: a comprehensive classification. Dermatology 2016; 232: 431–7.
- Chuh AA. Nomenclature of drug-induced pityriasis rosea-like rashes. Neuropsychiatr Dis Treat 2015; 11: 2547–9.
- Fox BJ, Odom RB. Papulosquamous diseases: a review. J Am Acad Dermatol 1985; 12: 597–624.
- Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol 2006; 54: 82–5.
- Castanedo-Cazares JP, Lepe V, Moncada B. Antivirals for pityriasis rosea. Photodermatol Photoimmunol Photomed 2004; 20: 110.
- Ehsani A, Esmaily N, Noormohammadpour P et al. The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea. Indian J Dermatol 2010; 55: 246–8.
- Rassai S, Feily A, Sina N, Abtahian S. Low dose of acyclovir may be an effective treatment against pityriasis rosea: a random investigator-blind clinical trial on 64 patients. J Eur Acad Dermatol Venereol 2011; 25: 24–6.
- Amatya A, Rajouria EA, Karn DK. Comparative study of effectiveness of oral acyclovir with oral erythromycin in the treatment of pityriasis rosea. Kathmandu Univ Med J (KUMJ) 2012; 10: 57–61.
- Ganguly S. A randomized, double-blind, placebo-controlled study of efficacy of oral acyclovir in the treatment of pityriasis rosea. J Clin Diagn Res 2014; 8: YC01–4.
- Das A, Sil A, Das NK et al. Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability. Indian Dermatol Online J 2015; 6: 181–4.
- Sharma PK, Yadav TP, Gautam RK et al. Erythromycin in pityriasis rosea: a double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 2000; 42: 241–4.
- Rasi A, Tajziehchi L, Savabi-Nasab S. Oral erythromycin is ineffective in the treatment of pityriasis rosea. J Drugs Dermatol 2008; 7: 35–8.
- Amer A, Fischer H. Azithromycin does not cure pityriasis rosea. Pediatrics 2006; 117: 1702–5.
- Pandhi D, Singal A, Verma P, Sharma R. The efficacy of azithromycin in pityriasis rosea: a randomized, double-blind, placebo-controlled trial. Indian J Dermatol Venereol Leprol 2014; 80: 36–40.
- Bukhari IA. Oral erythromycin is ineffective in the treatment of pityriasis rosea. J Drugs Dermatol 2008; 7: 625.
- Amatya A, Rajouria EA, Karn DK. Comparative study of effectiveness of oral acyclovir with oral erythromycin in the treatment of pityriasis rosea. Kathmandu Univ Med J (KUMJ) 2012; 10: 57–61.
- Arndt KA, Paul BS, Stern RS, Parrish JA. Treatment of pityriasis rosea with UV radiation. Arch Dermatol 1983; 119: 381–2.
- Leenutaphong V, Jiamton S. UVB phototherapy for pityriasis rosea: a bilateral comparison study. J Am Acad Dermatol 1995; 33: 996–9.
- Chuh AA, Dofitas BL, Comisel GG et al. Interventions for pityriasis rosea. Cochrane Database Syst Rev 2007; 2: CD005068.